


Article

# The zinc-binding domain of mammalian prolyl-tRNA synthetase is indispensable for catalytic activity and organism viability



Kommireddy Vasu, Iyappan Ramachandiran, Fulvia Terenzi, ..., Camelia Baleanu-Gogonea, Valentin Gogonea, Paul L. Fox

foxp@ccf.org

**HIGHLIGHTS**

Conserved zinc-binding domain (ZBD) of GluProRS is required for Pro-tRNA charging

ZBD stabilizes GluProRS and positions C-terminal carboxylate in the catalytic site

Embryonic lethality in mice with defective GluProRS ZBD reveals *in vivo* essentiality

Locked nucleic acid qPCR assay for CRISPR-mediated screening of chimeric mutant mice

Vasu et al., iScience 24, 102215  
March 19, 2021 © 2021 The Authors.  
<https://doi.org/10.1016/j.isci.2021.102215>



## Article

## The zinc-binding domain of mammalian prolyl-tRNA synthetase is indispensable for catalytic activity and organism viability

Kommireddy Vasu,<sup>1</sup> Iyappan Ramachandiran,<sup>1</sup> Fulvia Terenzi,<sup>1</sup> Debjit Khan,<sup>1</sup> Arnab China,<sup>1</sup> Krishnendu Khan,<sup>1</sup> Aayushi Chechi,<sup>1</sup> Camelia Baleanu-Gogonea,<sup>2</sup> Valentin Gogonea,<sup>1,2</sup> and Paul L. Fox<sup>1,\*</sup>

## SUMMARY

**Aminoacyl-tRNA synthetases (AARS) participate in decoding the genome by catalyzing conjugation of amino acids to their cognate tRNAs. During evolution, biochemical and environmental conditions markedly influenced the sequence and structure of the 20 AARSs, revealing adaptations dictating canonical and orthogonal activities. Here, we investigate the function of the appended Zn<sup>2+</sup>-binding domain (ZBD) in the bifunctional AARS, glutamyl-prolyl-tRNA synthetase (GluProRS). We developed GluProRS mutant mice by CRISPR-Cas9 with a deletion of 29 C-terminal amino acids, including two of four Zn<sup>2+</sup>-coordinating cysteines. Homozygous ZBD mutant mice die before embryonic day 12.5, but heterozygous mice are healthy. ZBD disruption profoundly reduces GluProRS canonical function by dual mechanisms: it induces rapid proteasomal degradation of the protein and inhibits ProRS aminoacylation activity, likely by sub-optimal positioning of ATP in the spatially adjacent catalytic domain. Collectively, our studies reveal the ZBD as a critical determinant of ProRS activity and GluProRS stability *in vitro* and *in vivo*.**

## INTRODUCTION

Aminoacyl tRNA synthetases (AARS) are essential enzymes that decode genetic information by recognizing specific tRNAs harboring appropriate anti-codon triplets and catalyzing ATP-dependent ligation to the cognate amino acid. Twenty AARSs, one for each proteinaceous amino acid, are found in the three kingdoms of life with limited exceptions in certain bacteria and archaea. Each AARS contains an anticodon-binding domain for tRNA recognition and binding, and a core catalytic domain for amino acid activation and transfer. In addition to the principal aminoacylation activity, eukaryotic AARS have acquired appended domains during evolution, generally at the N or C terminus, that display additional non-canonical functions beyond translation of the genetic code (Guo et al., 2010). The non-canonical activities are diverse in scope and contribute to development as well as pathology, e.g., tumorigenesis, obesity, angiogenesis, and inflammation (Guo and Schimmel, 2013; Kwon et al., 2019; Lee et al., 2018; Yao and Fox, 2013).

Of the 20 AARSs, the genes encoding GluRS and ProRS, i.e., *EARS* and *PARS*, are fused in metazoans to express the bifunctional GluProRS. The synthetase domains are joined by a non-catalytic linker containing a variable number of WHEP repeated domains: three in humans and mice (Ray and Fox, 2014). The fusion might be an evolutionary strategy to overcome adverse metabolic and environmental conditions (Eswarappa et al., 2018). Human GluProRS resides in a large, cytoplasmic multi-tRNA synthetase complex (MSC) containing seven other AARSs and three non-catalytic proteins. GluProRS is present as an obligate dimer (Khan et al., 2020; Quevillon et al., 1999). Several mutations in human *EPRS1* (the nuclear gene encoding GluProRS) cause severe, debilitating pathologies. For example, compound heterozygous (p.Pro1160Ser and p.Thr1223LeufsX3) and homozygous (p.Pro1115Arg and p.Met1126Thr) mutations in *EPRS1* cause juvenile-onset hypomyelinating leukodystrophy (Mendes et al., 2018). A recent study links a missense *EPRS1* mutation to a Parkinson disease (Yemni et al., 2019). In mice, a mutation in the GluProRS linker that abrogates phosphorylation leads to low body weight and increased lifespan (Arif et al., 2017). *Eprs1*-haploid mice exhibit enhanced viremia, inflammation, and delayed viral clearance (Lee et al., 2016). Cardiac-specific, *Eprs1* conditional knockout mice show reduced cardiac fibrosis under stress, suggesting that mild reduction of GluProRS expression is cardioprotective (Wu et al., 2020). At the


<sup>1</sup>Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA

<sup>2</sup>Department of Chemistry, Cleveland State University, Cleveland, OH, USA

\*Correspondence: foxp@ccf.org

<https://doi.org/10.1016/j.isci.2021.102215>





**Figure 1. Generation of *Eprs1* ZBD-defective mutant mice**

(A) Domain organization of human GluProRS; deletion start site (arrow).

(B) Sequence and secondary structure of human GluProRS ZBD. Horizontal arrows,  $\beta$ -sheets; “squiggly” lines,  $\alpha$ -helices; \*,  $\text{Zn}^{2+}$ -coordinating Cys residues;  $\Delta$ , identified SNPs; vertical arrow and dashed line indicate deletion.

(C) Design strategy for substitution in mouse *Eprs1* exon 32; red line indicates mutation site.

(D) Detailed schematic of region targeted by sgRNA 483.

(E) Sanger sequencing of genomic DNA from wild-type and *Eprs1*<sup>+/ $\Delta$ Z</sup> mice (arrow, insertion site).

cellular level, GluProRS exhibits several non-canonical activities. In interferon- $\gamma$ -activated myeloid cells, GluProRS forms a heterotetrameric, interferon- $\gamma$ -activated inhibitor of translation (GAIT) complex that binds and silences the translation of multiple mRNAs encoding inflammation-related proteins (Mukhopadhyay et al., 2009; Sampath et al., 2004). In adipocytes, insulin induces binding of GluProRS to fatty acid transport protein 1 and consequent transport to the plasma membrane for enhanced long-chain fatty acid uptake (Arif et al., 2017). With respect to therapeutic approaches, halofuginone, a plant alkaloid isolated from *Dichroa febrifuga* inhibits ProRS catalytic activity, and exhibits potent anti-fibrotic activity (Keller et al., 2012).

Mammalian bifunctional GluProRS has three appended domains lacking catalytic or substrate-binding activities: an N-terminal GST-like domain, three repeated WHEP domains in the linker joining the catalytic GluRS and ProRS domains, and the C-terminal ZBD (Figure 1A). A major function of the GST-like domain is to maintain structural integrity of the MSC by binary interactions with GST-like domains in other MSC constituents (Cho et al., 2015, 2019; Khan et al., 2020). In addition, following viral infection, the GST-like domain interacts with PCBP2, a negative regulator of MAVS, thereby enhancing antiviral activity (Lee et al., 2016). Several non-canonical functions of GluProRS are attributed to the WHEP domain-containing linker, including binding GAIT RNA elements and fatty acid transport protein 1 (Arif et al., 2017; Jia et al., 2008). In the C-terminal ZBD,  $\text{Zn}^{2+}$  is coordinated by four highly conserved Cys residues (Figures 1B and S1A). However, the functional significance of the mammalian ZBD remains unclear (Son et al., 2013; Yaremchuk et al., 2000; Zhou et al., 2013). Here, we have used CRISPR-Cas9 technology to generate a targeted mutation in the GluProRS ZBD causing a domain truncation that eliminates the terminal 29 amino acids and two of the four conserved  $\text{Zn}^{2+}$ -binding cysteine residues (Figures 1A and 1B). Homozygous mice carrying the mutant allele are embryonic-lethal, revealing the essentiality of the ZBD. Structural and biochemical analysis reveal that the ZBD is a critical determinant of ProRS catalytic activity and GluProRS stability.

## RESULTS

### Generation of *Eprs1* mutant mice with a partial $Zn^{2+}$ -binding domain deletion

The physiological significance of the GluProRS/ProRS ZBD has not been investigated in any model organism. The mouse and human ZBD amino acid sequences are homologous, with 88% identity and 95% similarity (Figure S1A). We generated an *Eprs1* CRISPR mutant with a frameshift mutation leading to premature termination of translation of the *Eprs1* gene. In mice, the ZBD occupies exons 31 and 32 at the terminus of the unspliced mRNA (Figure 1C). Targeting the 3' end of the *Eprs1* gene was accomplished by screening guide RNAs directed against the sequence. To prevent nonsense-mediated decay, exon 32 was selected for guide RNA screening. sgRNA 483 efficiently targeted the GluProRS C-terminal domain and was selected (Figures S2A and 1D). Interestingly, multiple non-synonymous SNPs were reported in human exon 32 that could potentially disrupt the ZBD (Figure 1B). Nuclear injection of CRISPR gRNA and Cas9 generated multiple allelic variants at the cut site with variable efficiency. Miseq analysis of the region surrounding the *Eprs1* target site c.4449 was performed in 23 founder chimeric mice to comprehensively profile mosaicism (Figure S2B). Non-homologous end joining repair resulted in insertion of a single adenine nucleotide at c.4449 that introduces a frameshift and an in-frame stop codon 11 nucleotides downstream (Figure 1E). The mutation caused deletion of the terminal 29 amino acids and loss of two of the four conserved Cys residues essential for binding one  $Zn^{2+}$  ion per monomer (Figure 1B). This truncated protein ( $\Delta Z$ ) harbors the entire catalytic and anti-codon binding domains. Two founder mice with high mutagenesis efficiency, and without other secondary mutations, were selected for breeding and experiments.


To detect the desired allele in F1 mice, we designed a novel locked nucleic acid (LNA)-containing fluorescent probe set to distinguish between the wild-type (WT) and mutant alleles that differ by a single nucleotide. Two primers that spanned the mutation site in *Eprs1* exon 32 resulted in amplification of a 103-bp segment (Figure S3A). One probe was conjugated with 5' HEX fluorophore and 3' IBFQ (Iowa Black fluorescent quencher) to detect the WT allele and another with 5' 6-FAM and 3' IBFQ to detect the mutant allele (Figure S3B). qPCR permitted definitive identification of all three mouse genotypes from tail DNA (Figure S3C). This qPCR design of LNA-based fluorescent probes can be generalized by others for distinguishing between alleles differing by a single nucleotide for routine screening of CRISPR-targeted mice.

### Homozygous partial deletion of *Eprs1* ZBD is embryonically lethal

Heterozygous *Eprs1*<sup>+/ $\Delta Z$</sup>  breeding pairs produced only *Eprs1*<sup>+/+</sup> and *Eprs1*<sup>+/ $\Delta Z$</sup>  offspring indicating that homozygous *Eprs1* deletion is embryonic-lethal (Figure 2A). To investigate the stage of lethality, timed mating of heterozygous breeding pairs was initiated, and the pregnancy was terminated at embryonic day 12.5. Embryos genotyped as *Eprs1*<sup>+/+</sup> and *Eprs1*<sup>+/ $\Delta Z$</sup>  appeared virtually identical and healthy; however, severely degenerate embryos were observed *in utero* and genotyped as homozygous *Eprs1* <sup>$\Delta Z$ / $\Delta Z$</sup>  mutants (Figure 2B). Embryonic lethality was observed in two independently derived mouse lines, providing evidence that the result was not due to an off-target effect of CRISPR-Cas9 gene editing. The number of embryos of each genotype revealed a near-Mendelian distribution, indicating a normal fertilization rate in the null mutant (Figure 2C). Owing to the profoundly abnormal condition of homozygous embryos, heterozygous mutant mice were selected for molecular analysis.

### Partial ZBD deletion reduces GluProRS expression

To investigate the mechanism underlying embryonic lethality accompanying ZBD disruption, GluProRS was determined in 3-week-old mouse brain lysates by immunoblot using an antibody targeting the linker region. GluProRS expression in *Eprs1*<sup>+/ $\Delta Z$</sup>  mice was about 50% of that in WT littermates, indicating that the mutant allele does not generate protein, or generates a rapidly degraded truncated protein (Figure 2D). To determine the potential role of defective transcription, *Eprs1* mRNA levels in brain tissue from WT and *Eprs1*<sup>+/ $\Delta Z$</sup>  mice were compared by qPCR. Essentially identical mRNA levels were observed in both genotypes indicating comparable transcription, and that the mutant transcript is not subject to nonsense-mediated decay (Figure 2E). Likewise, 3' RACE (rapid amplification of cDNA ends) analysis of *Eprs1* mRNA from WT and *Eprs1*<sup>+/ $\Delta Z$</sup>  mutant littermates, spanning exon 31 to the poly(A) tail, which includes the c.4449 insertion mutation in exon 32, showed identical splicing (Figure 2F). To assess a possible defect in nuclear export of mutant mRNA, we determined the intracellular distribution of the transcripts by fractionation of lysates followed by qPCR; fractionation efficacy was shown by immunoblot with antibodies against  $\alpha$ -tubulin and P80, markers of cytoplasm and nucleus, respectively (Figure 2G, right). The cytoplasmic-to-nuclear *Eprs1*



**Figure 2. Reduced GluProRS expression and embryonic lethality of *Eprs1* <sup>$\Delta Z/\Delta Z$</sup>  mice**

(A) Live births from matings of *Eprs1*<sup>+/ $\Delta Z$</sup>  mice.

(B and C) Embryo visualization (B) and genotype number (C) at E12.5 dpc following timed matings of *Eprs1*<sup>+/ $\Delta Z$</sup>  mice.

(D) GluProRS protein in wild-type and *Eprs1*<sup>+/ $\Delta Z$</sup>  mice from brain lysates was determined by immunoblot (above) and quantitated by densitometry (below; mean  $\pm$  SEM, n = 8).


(E) qPCR analysis of *Eprs1* mRNA levels in brain lysates from wild-type and *Eprs1*<sup>+/ $\Delta Z$</sup>  mice (ns = not significant; mean  $\pm$  SEM, n = 3).

(F) 3' RACE analysis to determine splicing of *Eprs1* mRNA in brain from wild-type and *Eprs1*<sup>+/ $\Delta Z$</sup>  mice: schematic of reverse transcription and amplification (left); visualization of splice product by agarose gel electrophoresis (right).

(G) Intracellular distribution of *EPRS1* mRNA (left) was determined by fractionation of lysates from HEK293 cells expressing wild-type or  $\Delta Z$  mutant, followed by RT-qPCR (mean  $\pm$  SEM, n = 3); lysates were subjected to immunoblot analysis for cytoplasmic and nuclear markers,  $\alpha$ -tubulin, and P80, respectively (right).

mRNA ratios were similar, indicating that nuclear export of mutant mRNA is not defective (Figure 2G, left) and that altered expression must be post-transcriptional.

To assess the role of translation, polysome-profiling was done with HEK293F cells stably transfected with FLAG-tagged human *EPRS1*, or a mutant encoding a 29-amino acid C-terminal deletion. Expression of mutant *EPRS1* mRNA did not affect global translation as shown by similar polysome loading (Figure 3A,



**Figure 3. Mutation in ZBD reduces GluProRS stability**

(A) Polysome profiling of HEK293 cells expressing wild-type (left) or  $\Delta Z$  mutant (center) *EPRS1* mRNA. Distribution of *EPRS1* mRNA in polysome and non-polysome fractions determined by RT-qPCR (right, ns = non-significant).

(B) To determine protein degradation rate, HEK293 cells expressing wild-type or  $\Delta Z$  mutant FLAG-GluProRS were treated with cycloheximide (CHX) in the presence or absence of MG132 for up to 16 h and lysates subjected to immunoblot analysis (left) and densitometric quantitation (right) (mean  $\pm$  SD, n = 3).

(C) Poly-ubiquitination of total protein in HEK293 cells expressing wild-type or  $\Delta Z$  mutant *EPRS1* was detected with anti-ubiquitin antibody (left) and quantitated by densitometry (right, mean  $\pm$  SEM, n = 3).

(D) Poly-ubiquitination of wild-type FLAG-GluProRS and  $\Delta Z$  mutant was determined in HEK293 cells treated with MG132 for 18 h. Lysates were subjected to immunoprecipitation (IP) with anti-FLAG antibody, followed by immunoblot with anti-ubiquitin, anti-FLAG, and anti- $\alpha$ -tubulin antibodies (left), and densitometric quantification (right; mean  $\pm$  SEM, n = 3; \*p < 0.05).

left). FLAG-*EPRS1* mRNA in polysomal and non-polysomal fractions was quantitated by RT-qPCR using primers specific for chimeric FLAG-*EPRS1*. Comparable ribosome loading was observed, indicating that translation of mutant *EPRS1* mRNA was not defective (Figure 3A, right). GluProRS half-life was measured in the presence of cycloheximide to inhibit protein synthesis. In HEK293F cells stably expressing WT FLAG-tagged GluProRS, the protein was stable for at least 16 h; in contrast, mutant GluProRS exhibited rapid turnover, with a half-life of about 5.6 h (Figure 3B). The proteasome inhibitor MG132 completely

blocked degradation of the mutant. To further explore the mechanism underlying degradation of the  $\Delta Z$  mutant, ubiquitination was determined. Total cell accumulation of poly-ubiquitinated protein was similar in HEK293F cells transfected with either GluProRS forms (Figure 3C). However, in the presence of MG132 to block proteasomal degradation, the ZBD mutant exhibited ~3.5-fold more ubiquitination compared to WT (Figure 3D), suggestive of a newly exposed site or an altered conformation in the truncated protein. Interestingly, despite the deleted domain, and the very low amount of ZBD mutant in cells, a co-immunoprecipitation experiment revealed normal interaction of the remnant with multiple other MSC constituents, indicating similar MSC incorporation of WT and ZBD-defective GluProRS (Figure S4).


### Proximity of the ProRS ZBD to the ATP-binding domain influences aminoacylation activity

The B-factor of a protein structure describes the degree of electron density spread for each atom, and is a measure of conformational flexibility (Ringe and Petsko, 1985); however, static disorder due to relative positional differences of atoms within a crystal can also contribute to high local B-factor. According to the crystal structure of human ProRS (PDB: 4HVC) the ZBD exhibits the relatively highest B-factor, indicative of conformational flexibility or flexible linkage to the body of the protein (Figure 4A). To visualize the altered structure of the mutant protein, theoretical solvent-accessible surface area (SASA) was determined for ProRS WT and  $\Delta Z$  structures in polar solvent. The SASA “rolling ball” algorithm rolls a theoretical sphere, with 1.4 Å radius, approximating a water molecule, to probe a macromolecule surface (Shrake and Rupley, 1973). ZBD deletion markedly increases solvent accessibility in the ATP-binding region of the catalytic domain, and to a lesser extent, a narrow region joining the anticodon-binding domain and ZBD (Figure 4B). These results are consistent with the position of the ZBD adjacent to the catalytic domain, despite its direct link in primary sequence to the anticodon-binding domain (Figure 4C). The human ZBD consists primarily of four  $\beta$  strands and two  $\alpha$  helices connected by unstructured loops (Figures 1B and 4D). The carboxylate group of Tyr<sup>1512</sup> is part of a network of charged interactions that includes Arg<sup>1163</sup>, Arg<sup>1278</sup>, and the  $\gamma$ -phosphate of the ATP analog (Figure 4E). Deletion of 29 C-terminal amino acids results in loss of the C-terminal-most  $\beta$  sheet and two of the four conserved Cys residues essential for tetrahedral coordination of Zn<sup>2+</sup> (Figures 1B and S5A).

Zn<sup>2+</sup> content of recombinant human wild-type and  $\Delta Z$  mutant ProRS was determined by Zn<sup>2+</sup> release by methyl methanethiosulfonate and spectroscopic detection with 4-(2-pyridylazo)resorcinol (Chongdar et al., 2015; Hunt et al., 1985). Unlike substantial Zn<sup>2+</sup> content of wild-type enzyme (Figure 4F, left), Zn<sup>2+</sup> in the  $\Delta Z$  mutant was virtually undetectable, consistent with the absence of two coordinating cysteine ligands (Figure 4F, right). AARSs catalyze tRNA aminoacylation in two steps. The amino acid is initially activated by ATP, generating a high-energy aminoacyl-adenylate intermediate. Subsequently, the aminoacyl-adenylate attacks the 3' OH tRNA terminus to form charged aminoacyl-tRNA. To determine the role of the ProRS ZBD in tRNA charging, we measured *in vitro* prolyl adenylation activity of recombinant proteins as transfer of L-[<sup>14</sup>C]proline to yeast tRNA. The  $\Delta Z$  mutant exhibited about a 90% loss of aminoacylation activity compared with wild-type ProRS (Figure 4G, top). We considered the possibility that the zinc ion was essential for ZBD conformation and aminoacylation activity. Chelation of Zn<sup>2+</sup> with 1,10-phenanthroline resulted in an ~80% loss of aminoacylation activity (Figure 4G, center). Based on proximity of the C terminus to the ATP-binding site (Figure 4D), we hypothesized that the ZBD was essential for positioning and orientation of the extreme C terminus in juxtaposition to ATP in the catalytic domain. Recombinant ProRS lacking the conserved Arg-Ser-Tyr from the C terminus ( $\Delta$ RSY) exhibited an ~80% reduction in aminoacylation activity compared with wild-type ProRS, nearly the same activity loss due to zinc depletion or due to the larger deletion in the  $\Delta Z$  mutant (Figure 4E, bottom). These results suggest that the primary role of Zn<sup>2+</sup> and the ZBD in catalysis is to direct orientation of the C terminus adjacent to the ATP-binding site of the catalytic domain.

## DISCUSSION

Domains appended to AARSs during evolution generate functional complexity, particularly in eukaryotes where they exhibit multiple non-canonical activities unrelated to their primary function in the interpretation of the genetic code (Guo et al., 2010). However, these apparently non-catalytic appendages can also modulate the canonical activity, for example, by regulating transferase activity or by facilitating amino acid editing activity (Bullwinkle and Ibba, 2014; Chang et al., 2016; Guo et al., 2009; He et al., 2009; Raben et al., 1994). Our experiments show the GluProRS ZBD is an appended domain essential for optimal transferase activity. In addition, the domain protects the protein from rapid degradation. In primary sequence space, the ProRS ZBD is an extension of the anticodon-binding domain, flexibly linked via a long  $\alpha$  helix (Figure 4C, left). Structurally, however, the primary interaction of the ZBD is with the ProRS catalytic domain.



**Figure 4. Zn<sup>2+</sup> and the ZBD are critical for ProRS aminoacylation activity**

(A) B-factor analysis of human ProRS dimer (PDB: 4HVC).  
 (B) SASA measurements were made using human ProRS dimer coordinates with and without the C-terminal 29-amino acids and probed with sphere of radius 1.4 Å. Difference in accessible surface area (mutant minus wild-type) at each residue is shown. Regions forming the ATP-binding pocket are indicated (red bars).  
 (C) Crystal structure of human ProRS monomer (PDB: 4HVC) highlighting ZBD (magenta), anticodon binding domain (ABD, blue), and catalytic domain (CD, green).  
 (D) Crystal structure of the ZBD showing Zn<sup>2+</sup> coordinated by four Cys residues and the C-terminal Tyr<sup>1512</sup> aligned with ATP analog (ATP<sup>a</sup>) and Pro substrates.  
 (E) Expanded view of human ProRS region surrounding C-terminal Tyr<sup>1512</sup> and ATP<sup>a</sup>. Charge interactions between Tyr<sup>1512</sup> carboxylate, Arg<sup>1278</sup>, Arg<sup>1163</sup>, and ATP<sup>a</sup> terminal phosphate are highlighted (dashed lines, distances in Å).  
 (F) Zn<sup>2+</sup> in wild-type (left) and ΔZ mutant (right) recombinant human ProRS was determined by methyl methanethiosulfonate (MMTS) and spectroscopic detection with 4-(2-pyridylazo)resorcinol (PAR).  
 (G) Aminoacylation activity of wild-type and ΔZ mutant ProRS was determined by incorporation of <sup>14</sup>C-labeled Pro into yeast tRNA (top), following treatment of wild-type ProRS with the Zn<sup>2+</sup> chelator, 1,10 phenanthroline (center), and in a mutant with deletion of the three terminal amino acids Arg-Ser-Tyr (bottom, ΔRSY) (mean ± SD, n = 3; \*\*p < 0.001).

Phylogenetic analysis showed segregation of C-terminal-bearing ZBD from ProRS (and GluProRS in species bearing the fused protein (Berthonneau and Mirande, 2000; Ray and Fox, 2014; Ray et al., 2011) into distinct classes. ZBD-bearing species form three major clusters bearing C-terminal-type ZBDs, comprising nearly all archaeal and eukaryal species and a subset of bacteria, likely sharing a common origin (Figure S1B).



The vast majority of bacteria lack the ProRS C-terminal ZBD including gram-negative bacteria, e.g., *Escherichia*, and nonproteobacteria, e.g., Chlamydiae. In archaea, the ProRS ZBDs are clustered in the four major phyla, namely, DPANN, TACK, Euryarchaeota, and Asgard. In eukaryotes, the ZBD is present in both free-standing ProRS and in the fused GluProRS. Eukaryotic mitochondrial ProRS does not contain a ZBD, consistent with the endosymbiont theory of evolution.

Among the mammalian AARSs, GluProRS is likely to have the most complex evolutionary history. The earliest appended domain in ProRS appears to be the C-terminal ZBD, likely appearing before the divergence of the three kingdoms (Figure S1B). GluRS gained an N-terminus GST-like domain in the fungal eukaryote, *S. cerevisiae* (Havrylenko and Mirande, 2015). This domain directs interactions with other proteins bearing GST-like domain and facilitates the formation of a 3-protein multi-tRNA synthetase complex in *S. cerevisiae*, and the 11-protein MSC in animals. The most recent addition is the WHEP domain, a helix-turn-helix structure appended to the GluRS C terminus in *Sphaeroforma arctica*, an early unicellular eukaryote closely related to animals (Ray and Fox, 2014). Remarkably, a fusion event between GluRS and ProRS occurred in an as-yet unidentified unicellular eukaryote, forming the heterobifunctional GluProRS, presumably bearing a single WHEP domain joining the AARSs. Nearly all animal species contain a fused GluProRS bearing zero to six WHEP domains formed by discrete duplication and loss events; humans and mice have three WHEP repeats (Ray et al., 2011).

Our results show that the ZBD is both essential for ProRS catalytic activity and contributes to stability. Its presence in all four major archaeal sub-clusters and certain bacterial phyla is potentially instructive with respect to environmental or other forces driving its origin. Hyperthermic conditions and lateral gene transfer might have driven adaptations that enhanced stability (Groussin and Gouy, 2011; Reed et al., 2013). The tetrahedral interaction of  $Zn^{2+}$  with four cysteines renders the cation nearly inert chemically, and commonly,  $Zn^{2+}$ -cysteine complexes perform structural functions within proteins (Pace and Weerapana, 2014). Both  $Mg^{2+}$  and  $Zn^{2+}$  are frequently observed in AARS crystal structures.  $Mg^{2+}$  generally functions to stabilize the transition state of ATP during hydrolysis, whereas the role of  $Zn^{2+}$  in AARS function is variable. In AARSs that ligate Ile, Leu, Val, Glu, Gln, Trp, and Met,  $Zn^{2+}$  contributes to efficient catalysis. TrpRS contains a consensus ZBD, and is activated by  $Zn^{2+}$ ; however,  $Zn^{2+}$  has not been observed in multiple crystal structures suggesting weak interaction with the ZBD (Doublet et al., 1995; Xu et al., 2018; Yang et al., 2007).  $Zn^{2+}$  can contribute to AARS discrimination between cognate and non-cognate amino acids. For example, when bound to *E. coli* ThrRS, the hydroxyl side chain of Thr switches  $Zn^{2+}$  geometry from tetrahedral to the active pentacoordinate intermediate (Sankaranarayanan et al., 2000). The methyl group side chain of non-cognate Val cannot co-ordinate with  $Zn^{2+}$  and is rejected. Similar amino acid selectivity is exhibited by *E. coli* CysRS where Cys forms a  $Zn^{2+}$ -thiolate bond that directs a 20,000-fold discrimination against Ser (Zhang et al., 2003). SerRS of methanogenic bacteria exhibits a similar discrimination mechanism:  $Zn^{2+}$  coordination with Ser facilitates activation, but the longer side chain of Thr induces a steric clash that prevents activation (Bilokapic et al., 2006).

Our experiments with the recombinant ProRS region of human GluProRS show that a 29-amino acid deletion at the C terminus, that removes two of the four  $Zn^{2+}$ -coordinating ligands, inhibits  $Zn^{2+}$ -binding and ProRS aminoacylation activity. We also show that  $Zn^{2+}$  depletion with a chelator or deletion of three C-terminal amino acids, Arg-Ser-Tyr, inhibits aminoacylation activity. Together, these results reveal a key role of  $Zn^{2+}$  and the ZBD in catalysis. Importantly, the terminal three amino acids are highly conserved, and a consensus sequence of Arg/Lys-Ser/Thr/Ala-Tyr are present at the C terminus of ProRS enzymes containing a ZBD from bacteria to humans (Yaremchuk et al., 2000) (Figure S1A).

The ProRS ZBDs of mammals and *Thermus thermophilus* exhibit considerable sequence similarity, including a conserved terminal Tyr residue (Figure S1A). Likewise, overlay of the crystal structure of *T. thermophilus* (Crepin et al., 2006; Yaremchuk et al., 2000, 2001) and human ProRS reveals nearly identical structures in the active site region surrounding the terminal Tyr and ATP (Figure S5B). In *T. thermophilus*, based on the proximity of the terminal Tyr<sup>477</sup> to Arg<sup>264</sup>, Arg<sup>152</sup>, and the  $\gamma$ -phosphate of ATP, a network of attractive electrostatic interactions was proposed to maintain a bent conformation of ATP for optimal reaction with the adjacent Pro substrate (Yaremchuk et al., 2001) (Figure S5B). The function of the terminal Tyr was clarified by finding that mutation to Phe or Ala in *T. thermophilus* only slightly reduced aminoacylation activity, suggesting the carboxylate group, rather than the amino acid side chain, is effective (Yaremchuk et al., 2000). A similar charge network in human ProRS consists of the C-terminal Tyr<sup>1512</sup>, Arg<sup>1163</sup>, Arg<sup>1278</sup>, and ATP (Figure 4E). The carboxylate group of Tyr<sup>1512</sup> is 4.5 Å

from the  $\gamma$ -phosphate group of ATP and forms a linear axis with the Pro substrate (Figures 4D and 4E). We propose that, in addition to the attractive interactions of Tyr carboxylate with the Arg amines, an electrostatic repulsion with the  $\gamma$ -phosphate drives ATP toward Pro for more efficient reaction to form the prolyl-adenylate intermediate. A second ZBD function is GluProRS stabilization, possibly by masking an ubiquitination site. These structure-activity relationships raise the possibility that the ZBD might contribute to physiological regulation of the catalytic activity of the ProRS domain, or pathological dysregulation of protein synthesis due to deficient aminoacylation activity or high enzyme turnover.

### Limitations of the study

We have investigated the role of the ZBD in the canonical function of human ProRS, i.e., charging to the tRNA synthetase. We have not considered non-canonical functions potentially exhibited by the ZBD, a possibility given the structural similarity studies of the *T. thermophilus* ZBD with the C-terminal domain of translation initiation factor 3 from *Bacillus stearothermophilus*. Likewise, our study focuses on the effect of ZBD on prolyl-tRNA synthetase function, and does not consider potential long-range interactions that extend to the GluRS region of the bifunctional enzyme. We show that ZBD-deleted GluProRS is incorporated into the MSC; however, its influence on the structure of the MSC has not been investigated. CRISPR-mediated mutation induced a frameshift that appended four amino acids not present in mouse ProRS, i.e., Lys-Pro-Ser-Val, before a stop codon terminated translation. The present study proposes a reaction mechanism based on X-ray crystallography and limited mutagenesis studies by us and others. A more detailed study involving molecular dynamics simulation and guided mutagenesis would give more insights into the role of the C-terminal ZBD in the reaction mechanism.

### Resource availability

#### Lead contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Paul Fox ([foxp@ccf.org](mailto:foxp@ccf.org)).

#### Materials availability

All plasmids and mouse lines generated in this study will be made available on request, but we may require a completed Materials Transfer Agreement if there is potential for commercial application.

#### Data and code availability

This study did not generate datasets or analyze code.

## METHODS

All methods can be found in the accompanying [Transparent Methods supplemental file](#).

## SUPPLEMENTAL INFORMATION

Supplemental information can be found online at <https://doi.org/10.1016/j.isci.2021.102215>.

## ACKNOWLEDGMENTS

We thank the Case Western Reserve University Transgenic and Targeting Facility and the Genomics Core, both of Case Western Reserve University, for their services in generating and validating the mutant mouse. This project was supported by NIH grants P01 HL076491, R01 DK123236, and R01 AG067146 (to P.L.F.), by a Clinical and Translational Science Collaborative (CTSC) Core Utilization Pilot Grant Award from Case Western Reserve University School of Medicine (to P.L.F.), and by American Heart Association (AHA) Postdoctoral Fellowships, Nationwide (19POST34380725 to I.R. and 19POST34380687 to D.K.).

## AUTHOR CONTRIBUTIONS

K.V.: conceptualization, methodology, investigation, analysis, writing – original draft, review & editing; I.R.: investigation, methodology; D.K.: methodology, resources, investigation; A.C.: methodology, resources, investigation; F.T.: methodology, resources, investigation; A.C.: methodology, investigation; K.K.: methodology, resources, investigation; C.B.G.: visualization and formal analysis; V.G.: visualization, formal analysis; P.L.F.: conceptualization, supervision, project administration, funding Acquisition, writing – review & editing.

## DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: November 11, 2020

Revised: January 26, 2021

Accepted: February 17, 2021

Published: March 19, 2021

## REFERENCES

- Arif, A., Terenzi, F., Potdar, A.A., Jia, J., Sacks, J., China, A., Halawani, D., Vasu, K., Li, X., Brown, J.M., et al. (2017). EPRS is a critical mTORC1-S6K1 effector that influences adiposity in mice. *Nature* 542, 357–361.
- Berthonneau, E., and Mirande, M. (2000). A gene fusion event in the evolution of aminoacyl-tRNA synthetases. *FEBS Lett.* 470, 300–304.
- Bilokapic, S., Maier, T., Ahel, D., Gruic-Sovulj, I., Soll, D., Weygand-Durasevic, I., and Ban, N. (2006). Structure of the unusual seryl-tRNA synthetase reveals a distinct zinc-dependent mode of substrate recognition. *EMBO J.* 25, 2498–2509.
- Bullwinkle, T.J., and Ibbas, M. (2014). Emergence and evolution. *Top. Curr. Chem.* 344, 43–87.
- Chang, C.Y., Chien, C.I., Chang, C.P., Lin, B.C., and Wang, C.C. (2016). A WHEP domain regulates the dynamic structure and activity of *Caenorhabditis elegans* glycyl-tRNA synthetase. *J. Biol. Chem.* 291, 16567–16575.
- Cho, H.Y., Lee, H.J., Choi, Y.S., Kim, D.K., Jin, K.S., Kim, S., and Kang, B.S. (2019). Symmetric assembly of a decameric subcomplex in human multi-tRNA synthetase complex via interactions between glutathione transferase-homology domains and aspartyl-tRNA synthetase. *J. Mol. Biol.* 431, 4475–4496.
- Cho, H.Y., Maeng, S.J., Cho, H.J., Choi, Y.S., Chung, J.M., Lee, S., Kim, H.K., Kim, J.H., Eom, C.Y., Kim, Y.G., et al. (2015). Assembly of multi-tRNA synthetase complex via heterotetrameric glutathione transferase-homology domains. *J. Biol. Chem.* 290, 29313–29328.
- Chongdar, N., Dasgupta, S., Datta, A.B., and Basu, G. (2015). Dispensability of zinc and the putative zinc-binding domain in bacterial glutamyl-tRNA synthetase. *Biosci. Rep.* 35, e00184.
- Crepin, T., Yaremchuk, A., Tukalo, M., and Cusack, S. (2006). Structures of two bacterial prolyl-tRNA synthetases with and without a cis-editing domain. *Structure* 14, 1511–1525.
- Doublet, S., Bricogne, G., Gilmore, C., and Carter, C.W., Jr. (1995). Tryptophanyl-tRNA synthetase crystal structure reveals an unexpected homology to tyrosyl-tRNA synthetase. *Structure* 3, 17–31.
- Eswarappa, S.M., Potdar, A.A., Sahoo, S., Sankar, S., and Fox, P.L. (2018). Metabolic origin of the fused aminoacyl-tRNA synthetase, glutamyl-prolyl-tRNA synthetase. *J. Biol. Chem.* 293, 19148–19156.
- Grossin, M., and Gouy, M. (2011). Adaptation to environmental temperature is a major determinant of molecular evolutionary rates in archaea. *Mol. Biol. Evol.* 28, 2661–2674.
- Guo, M., Chong, Y.E., Beebe, K., Shapiro, R., Yang, X.L., and Schimmel, P. (2009). The C-Ala domain brings together editing and aminoacylation functions on one tRNA. *Science* 325, 744–747.
- Guo, M., and Schimmel, P. (2013). Essential nontranslational functions of tRNA synthetases. *Nat. Chem. Biol.* 9, 145–153.
- Guo, M., Yang, X.L., and Schimmel, P. (2010). New functions of aminoacyl-tRNA synthetases beyond translation. *Nat. Rev. Mol. Cell Biol.* 11, 668–674.
- Havrylenko, S., and Mirande, M. (2015). Aminoacyl-tRNA synthetase complexes in evolution. *Int. J. Mol. Sci.* 16, 6571–6594.
- He, R., Zu, L.D., Yao, P., Chen, X., and Wang, E.D. (2009). Two non-redundant fragments in the N-terminal peptide of human cytosolic methionyl-tRNA synthetase were indispensable for the multi-synthetase complex incorporation and enzyme activity. *Biochim. Biophys. Acta* 1794, 347–354.
- Hunt, J.B., Neece, S.H., and Ginsburg, A. (1985). The use of 4-(2-pyridylazo)resorcinol in studies of zinc release from *Escherichia coli* aspartate transcarbamoylase. *Anal. Biochem.* 146, 150–157.
- Jia, J., Arif, A., Ray, P.S., and Fox, P.L. (2008). WHEP domains direct noncanonical function of glutamyl-prolyl tRNA synthetase in translational control of gene expression. *Mol. Cell* 29, 679–690.
- Keller, T.L., Zocco, D., Sundrud, M.S., Hendrick, M., Edenius, M., Yum, J., Kim, Y.J., Lee, H.K., Cortese, J.F., Wirth, D.F., et al. (2012). Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase. *Nat. Chem. Biol.* 8, 311–317.
- Khan, K., Beleanu Gogonea, C., Willard, B., Gogonea, V., and Fox, P.L. (2020). 3-Dimensional architecture of the human multi-tRNA synthetase complex. *Nucleic Acids Res.* 48, 8740–8754.
- Kwon, N.H., Fox, P.L., and Kim, S. (2019). Aminoacyl-tRNA synthetases as therapeutic targets. *Nat. Rev. Drug Discov.* 18, 629–650.
- Lee, E.Y., Kim, S., and Kim, M.H. (2018). Aminoacyl-tRNA synthetases, therapeutic targets for infectious diseases. *Biochem. Pharmacol.* 154, 424–434.
- Lee, E.Y., Lee, H.C., Kim, H.K., Jang, S.Y., Park, S.J., Kim, Y.H., Kim, J.H., Hwang, J., Kim, J.H., Kim, T.H., et al. (2016). Infection-specific phosphorylation of glutamyl-prolyl tRNA synthetase induces antiviral immunity. *Nat. Immunol.* 17, 1252–1262.
- Mendes, M.I., Gutierrez Salazar, M., Guerrero, K., Thiffault, I., Salomons, G.S., Gauquelin, L., Tran, L.T., Forget, D., Gauthier, M.S., Waisfisz, Q., et al. (2018). Bi-allelic mutations in EPRS, encoding the glutamyl-prolyl-aminoacyl-tRNA synthetase, cause a hypomyelinating leukodystrophy. *Am. J. Hum. Genet.* 102, 676–684.
- Mukhopadhyay, R., Jia, J., Arif, A., Ray, P.S., and Fox, P.L. (2009). The GAIT system: a gatekeeper of inflammatory gene expression. *Trends Biochem. Sci.* 34, 324–331.
- Pace, N.J., and Weerapana, E. (2014). Zinc-binding cysteines: diverse functions and structural motifs. *Biomolecules* 4, 419–434.
- Quevillon, S., Robinson, J.C., Berthonneau, E., Siatecka, M., and Mirande, M. (1999). Macromolecular assemblage of aminoacyl-tRNA synthetases: identification of protein-protein interactions and characterization of a core protein. *J. Mol. Biol.* 285, 183–195.
- Raben, N., Nichols, R., Dohlman, J., McPhie, P., Sridhar, V., Hyde, C., Leff, R., and Plotz, P. (1994). A motif in human histidyl-tRNA synthetase which is shared among several aminoacyl-tRNA synthetases is a coiled-coil that is essential for enzymatic activity and contains the major autoantigenic epitope. *J. Biol. Chem.* 269, 24277–24283.
- Ray, P.S., and Fox, P.L. (2014). Origin and evolution of glutamyl-prolyl tRNA synthetase WHEP domains reveal evolutionary relationships within Holozoa. *PLoS One* 9, e98493.
- Ray, P.S., Sullivan, J.C., Jia, J., Francis, J., Finnerty, J.R., and Fox, P.L. (2011). Evolution of function of a fused metazoan tRNA synthetase. *Mol. Biol. Evol.* 28, 437–447.
- Reed, C.J., Lewis, H., Trejo, E., Winston, V., and Evilia, C. (2013). Protein adaptations in archaeal extremophiles. *Archaea* 2013, 373275.
- Ringe, D., and Petsko, G.A. (1985). Mapping protein dynamics by X-ray diffraction. *Prog. Biophys. Mol. Biol.* 45, 197–235.
- Sampath, P., Mazumder, B., Seshadri, V., Gerber, C.A., Chavatte, L., Kinter, M., Ting, S.M., Dignam, J.D., Kim, S., Driscoll, D.M., and Fox, P.L. (2004). Noncanonical function of glutamyl-prolyl-tRNA synthetase: gene-specific silencing of translation. *Cell* 119, 195–208.
- Sankaranarayanan, R., Dock-Bregeon, A.C., Rees, B., Bovee, M., Caillet, J., Romby, P., Francklyn, C.S., and Moras, D. (2000). Zinc ion-mediated

amino acid discrimination by threonyl-tRNA synthetase. *Nat. Struct. Biol.* 7, 461–465.

Shrake, A., and Rupley, J.A. (1973). Environment and exposure to solvent of protein atoms. Lysozyme and insulin. *J. Mol. Biol.* 79, 351–371.

Son, J., Lee, E.H., Park, M., Kim, J.H., Kim, J., Kim, S., Jeon, Y.H., and Hwang, K.Y. (2013). Conformational changes in human prolyl-tRNA synthetase upon binding of the substrates proline and ATP and the inhibitor halofuginone. *Acta Crystallogr. D Biol. Crystallogr.* 69, 2136–2145.

Wu, J., Subbaiah, K.C.V., Xie, L.H., Jiang, F., Khor, E.S., Mickelsen, D., Myers, J.R., Tang, W.H.W., and Yao, P. (2020). Glutamyl-prolyl-tRNA synthetase regulates proline-rich pro-fibrotic protein synthesis during cardiac fibrosis. *Circ. Res.* 127, 827–846.

Xu, X., Zhou, H., Zhou, Q., Hong, F., Vo, M.N., Niu, W., Wang, Z., Xiong, X., Nakamura, K., Wakasugi,

K., et al. (2018). An alternative conformation of human TrpRS suggests a role of zinc in activating non-enzymatic function. *RNA Biol.* 15, 649–658.

Yang, X.L., Guo, M., Kapoor, M., Ewalt, K.L., Otero, F.J., Skene, R.J., McRee, D.E., and Schimmel, P. (2007). Functional and crystal structure analysis of active site adaptations of a potent anti-angiogenic human tRNA synthetase. *Structure* 15, 793–805.

Yao, P., and Fox, P.L. (2013). Aminoacyl-tRNA synthetases in medicine and disease. *EMBO Mol. Med.* 5, 332–343.

Yaremchuk, A., Cusack, S., and Tukalo, M. (2000). Crystal structure of a eukaryote/archaeon-like prolyl-tRNA synthetase and its complex with tRNA<sup>Pro</sup>(CGG). *EMBO J.* 19, 4745–4758.

Yaremchuk, A., Tukalo, M., Grotli, M., and Cusack, S. (2001). A succession of substrate induced conformational changes ensures the

amino acid specificity of *Thermus thermophilus* prolyl-tRNA synthetase: comparison with histidyl-tRNA synthetase. *J. Mol. Biol.* 309, 989–1002.

Yemni, E.A., Monies, D., Alkhairallah, T., Bohlega, S., Abouelhoda, M., Magrashi, A., Mustafa, A., AlAbdulaziz, B., Alhamed, M., Baz, B., et al. (2019). Integrated analysis of whole exome sequencing and copy number evaluation in Parkinson's disease. *Sci. Rep.* 9, 3344.

Zhang, C.M., Christian, T., Newberry, K.J., Perona, J.J., and Hou, Y.M. (2003). Zinc-mediated amino acid discrimination in cysteinyl-tRNA synthetase. *J. Mol. Biol.* 327, 911–917.

Zhou, H., Sun, L., Yang, X.L., and Schimmel, P. (2013). ATP-directed capture of bioactive herbal-based medicine on human tRNA synthetase. *Nature* 494, 121–124.

iScience, Volume 24


## **Supplemental information**

**The zinc-binding domain of mammalian  
prolyl-tRNA synthetase is indispensable  
for catalytic activity and organism viability**

**Kommireddy Vasu, Iyappan Ramachandiran, Fulvia Terenzi, Debjit Khan, Arnab China, Krishnendu Khan, Aayushi Chechi, Camelia Baleanu-Gogonea, Valentin Gogonea, and Paul L. Fox**

**A**

Tt TRKVDTYEAFKEAVQEGF-ALAFHCGDKACERLIQEETT-----ATTRCVPF EAEPE--EGF-CVRCGRPSAYGKR VVFAKAY  
 Hs M VVANTMEDFQKILDSGKIVQIPFCGEIDCEDWIKKTTARDQDLEPGAPSMGAKSLCIPFKPLCELQPGAKCV-CGKNPAK-YYTLFGRSY  
 Mm M VVSNLTLEDQKVLDAKVAQIPFCGEIDCEDWIKKMTARDQDVEPGAPSMGAKSLCIPFNPLCELQPGAMCV-CGKNPAK-FYTLFGRSY  
 : \* \* \* : : : \* . . \* \* : \* \* \* : \* : \* \* \* : \* \* \* \* : \* . . \* : : \*


**B**

**Figure S1. The ProRS ZBD in the three kingdoms of life. Related to Figure 1.**

(A) Multiple sequence alignment of ProRS ZBD in *Thermus thermophilus* (Tt), *Homo sapiens* (Hs), and *Mus musculus* (Ms). Sequence identity (\*), strong homology (:), and weak homology (.) are indicated below, and Zn<sup>2+</sup>-binding Cys residues above (•)

(B) The ProRS C-terminal ZBD is present in some (red) but not other (black) bacteria, archaea (magenta), and in eukarya with separate ProRS (blue) or fused GluProRS (green).






**Figure S3. Novel locked nucleic acid-based detection of mutant allele. Related to Figure 2.**

(A) Locked nucleic acid probe design for detection of wild-type and mutant mouse tail DNA using FAM and HEX fluorophores and IBFQ. Locked nucleic acid bases are underlined (blue).

(B) Allele discrimination plot showing segregation of DNA from homozygous wild-type and *Eprs1*<sup>+/ $\Delta$ Z</sup> mice.


(C) qPCR curves showing amplification and selective detection using wild-type (left) and mutant (right) probe sets.





**Figure S4. Incorporation of wild-type and  $\Delta Z$  mutant GluProRS in the MSC. Related to Figure 3.**

HEK293F cells expressing FLAG-tagged wild-type or  $\Delta Z$  mutant *EPRS1* were subjected to immunoprecipitation (IP) with anti-FLAG antibody, followed by immunoblot with antibodies against MSC constituents. To take into consideration the low steady-state level of the  $\Delta Z$  mutant, 3.5-times more eluate from the mutant cells was loaded onto the gel.



**Figure S5. X-ray crystal structures of zinc-binding and catalytic domains of human ProRS. Related to Figure 4.**

(A) Depiction of ZBD structure in which the terminal 29 amino acids are removed; deleted segment is lightened.

(B) Overlay of region surrounding terminal Tyr and ATP from human (green) and *Thermus thermophilus* (cyan) ProRS.

## Transparent Methods

### Cell culture, reagents, and antibodies

HEK293F cells were cultured in high-glucose DMEM supplemented with 10% fetal bovine serum and 4 mM L-glutamine. Cycloheximide and 1,10 phenanthroline were obtained from Sigma-Aldrich (St. Louis, MO), and MG132 from Cell Signaling (Beverly, MA). Antibodies against FLAG peptide and P80 were from Genscript (Piscataway, NJ). Antibodies against MetRS, AspRS, GlnRS, AIMP1, AIMP2, AIMP3, ubiquitin, GAPDH,  $\alpha$ -tubulin, and  $\beta$ -actin were purchased from Proteintech (Rosemont, IL). Rabbit anti-human GluProRS-linker antibody was generated as described (Jia et al., 2008)

### cDNA cloning and constructs

For bacterial expression, human *PARS* cDNA was cloned with N-terminal His tag in pTrcHisB (ThermoFisher) by PCR using human *EPRS1* cDNA (Halawani et al., 2018). For mammalian expression, human *EPRS1* cDNA was cloned with N-terminal 3X-FLAG tag in pLenti under an EF-1 $\alpha$  promoter, and stably expressed following lentiviral transduction with in HEK293F cells. For mutagenesis experiments, Q5<sup>®</sup> Site-Directed Mutagenesis Kit (New England Biolabs, Ipswich, MA) was used according to the manufacturer's instructions. Primer sequences and annealing temperatures were generated with NEBaseChanger<sup>™</sup>. The  $\Delta$ Z mutant was generated by deleting 29 amino acids from the C-terminus of ProRS by mutagenesis of wild-type constructs. All *PARS* and *EPRS1* cDNA constructs were verified by sequencing.

### Generation of knock-in mice by Crispr/Cas9

CRISPR guide RNAs were designed by CRISPOR (<http://crispor.tefor.net/>), *in vitro*-synthesized, and screened using Guide-it<sup>™</sup> Complete sgRNA Screening System (Takara Bio, Mountain View, CA). ZBD knock-in mice were generated using Crispr/Cas9 technology by the Case Western Reserve University (CWRU) Transgenic Core. *In vitro* screened gRNA (sgRNA 483) and Cas9 nuclease were injected into fertilized C57BL/6J

oocytes. For Miseq analysis of mosaic F0 founder mice, tail clip genomic DNA was subjected to deep sequencing. A 250-bp region spanning the target site was PCR-amplified using tagged primers (forward: TCCCTACACGACGCTCTTCCGATCT; reverse AGTTCAGACGTGTGCTCTTCCGATCT). Bar-coded amplicons were sequenced in parallel by MiSeq at CWRU Genomics Core. The strategy targeted mutation of a single nt at c.4449 near the 3' end of *EPRS1* mRNA; however, non-homologous end joining repair resulted in serendipitous insertion of a single adenine at the site. The insertion induced a frame-shift that appended 4 extraneous amino acids, Lys-Pro-Ser-Val, before a stop codon terminated translation. All mouse husbandry and experiments were performed in compliance with procedures approved by the Cleveland Clinic Lerner Research Institute Institutional Animal Care and Use Committee.

### **Locked nucleic acid-based detection of mutant allele**

Amplification primers and LNA target probes were designed to detect editing events at the Cas9 cleavage site. The target site was amplified using forward and reverse primers, AACCTGGTGCTCCATCC and GATTCTTGCCACAGACACAC, respectively. Using OligoAnalyzer, allele-specific LNA probes were designed to exhibit a  $\Delta T_m > 15$  °C by addition of up to 6 modified nucleotides surrounding the altered nucleotide, and were synthesized by Integrated DNA Technologies (IDT; Coralville, IA). The wild-type allele probe was labeled with 5' Hex (absorbance at 555 nm) and 3' Iowa Black Fluorophore Quencher (IBFQ). Mutant allele probe was labeled with 5' FAM (absorbance at 520 nm) and 3' IBFQ. The qPCR assays were performed on a StepOnePlus thermocycler (ThermoFisher Scientific) using PrimeTime<sup>®</sup> Gene Expression Master Mix (IDT).

### **Phylogenetic analysis**

Amino acid sequences for phylogenetic analysis were collected from the non-redundant protein sequence database at NCBI. Human ProRS orthologs were identified by BLASTP using pairwise alignment view, E-value threshold of 10, and BLOSUM62

scoring matrix. Proteins in each genus were selected for maximal E-value and conserved ZBD, and sequences not annotated as ProRS removed. ZBD sequence conservation was determined using CLUSTAL Omega. Phylogenetic reconstructions were built using the function "build" of ETE3 v3.1.1 (Huerta-Cepas et al., 2016) as implemented on GenomeNet (<https://www.genome.jp/tools/ete/>). The tree was constructed using FastTree v2.1.8 with default parameters.

### **Solvent-accessible surface area measurement**

Solvent-accessible surface area was determined in wild-type and  $\Delta Z$  mutant human ProRS (PDB ID: 4HVC) using GETAREA (Sealy Center for Structural Biology, University of Texas Medical Branch, Galveston). A sphere of radius 1.4 Å, approximating a water molecule was used as probe. The difference in solvent-accessible surface area was calculated by subtracting the ratio of side-chain surface area to random coil value for each residue of wild-type structure from the mutant structure lacking the ZBD.

### **RT-PCR analysis**

Total mouse RNA was isolated with Trizol, and subjected to reverse transcription and real-time PCR using AgPath-ID One-Step RT-PCR reagent (Ambion). TaqMan probes specific for *EPRS1*,  $\beta$ -actin and GAPDH (Applied Biosystems) were used. For qPCR analysis of polysome fractions, total RNA was isolated from the combined fractions by extraction with Trizol LS reagent and purified by RNeasy minikit (Qiagen, Valencia, CA). The RNA was quantitated and used for real-time PCR analysis.

### **Immunoblot Analysis**

Tissue or cell lysates were denatured and resolved on 4–20% gradient SDS-PAGE. After transfer, the blots were probed with specific primary antibody followed by HRP-conjugated secondary antibody, and developed using ECL or ECL plus reagent (GE Healthcare).

### **Isolation of nuclear and cytoplasmic RNA fractions**

Nuclear and cytoplasmic RNA fractions were isolated using phenol-free, small-scale Protein and RNA Isolation System (PARIS™, ThermoFisher). Total, cytoplasmic, and nuclear fractions were isolated from  $10^6$  HEK293F cells and RNA was isolated, treated with RNase-free DNase and used for qPCR analysis.

### **3' RACE analysis**

3' RACE was done as described (Scotto-Lavino et al., 2006). Briefly, total RNA was isolated from mouse brain using Trizol, and cDNA was generated by reverse transcription followed by PCR using SuperScript III One-Step RT-PCR System (Invitrogen). The 52-nt ( $Q_0$ - $Q_1$ -T) CCAGTGAGCAGAGTGACGAGGACTCGAGCTCAAGCTTTTTTTTTTTTTTTTTTTT primer was used to reverse transcribe cellular mRNAs. Primers  $Q_0$ -CCAGTGAGCAGAGTGACG,  $Q_1$ -GAGGACTCGAGCTCAAGC and gene-specific primers GSP1-GATGCTGGAAAGGTTGCACAGATTC and GSP2-CATTTTGTGGGGAAATTGACT were used in sequential amplifications to generate sequence-specific product.

### **Polysome profiling**

Isolation of ribosome-rich, translationally-active and ribosome-poor, inactive mRNA pools was done by sucrose gradient fractionation. Cycloheximide (100  $\mu$ g/mL) was added to  $10^6$  HEK293F cells for 20 min, and cells collected by low-speed centrifugation and washed twice with cycloheximide-containing, ice-cold PBS. Cell pellets were suspended in 350  $\mu$ L of lysis buffer (10 mM Tris pH 7.4, 5 mM  $MgCl_2$ , 100 mM KCl, 1% Triton X-100, 0.5% deoxycholate, 2 mM DTT, 100  $\mu$ g/mL cycloheximide, and RNase inhibitor) and incubated for 5 min on ice. The lysates were centrifuged at 15,000 g for 10 min and supernatants collected. RNase inhibitor (5  $\mu$ L, 40 U/ $\mu$ L) and cycloheximide (100  $\mu$ g/mL) were added to 50 ml each of freshly prepared 10% and 50% sucrose gradient solutions (20 mM HEPES pH 7.4, 100 mM KCl, 5 mM  $MgCl_2$ , and 2 mM DTT) just

before use. Lysates were loaded onto the sucrose gradient and centrifuged at 29,000 rpm for 4 h, and 8 fractions of about 1 mL were collected and combined. Fractions containing light ribonucleoproteins, 40S, 60S, and 80S ribosomes formed the translationally-inactive pool, and heavy polysome fractions formed the translationally-active pool.

### **Measurement of protein degradation**

HEK293F cells stably expressing wild-type or mutant *EPRS1* cDNA with N-terminal 3X FLAG tag were used. Cells ( $1 \times 10^6$  cells) were incubated with cycloheximide (50  $\mu\text{g}/\text{mL}$ ) in 4 mL of DMEM for up to 16 h, harvested, and lysed. Lysates were probed by immunoblot with anti-FLAG antibody. For proteasome inhibition, cells were incubated with 10  $\mu\text{M}$  MG132.

### **Determination of ProRS-bound $\text{Zn}^{2+}$**

$\text{Zn}^{2+}$  content of recombinant, wild-type human ProRS and ZBD mutant were measured spectrophotometrically (Chongdar et al., 2015; Hunt et al., 1985). Cysteines were modified with MMTS (100  $\mu\text{M}$ ) to release protein-bound  $\text{Zn}^{2+}$ , and released  $\text{Zn}^{2+}$  detected with 50  $\mu\text{M}$  PAR in 50 mM Tris-HCl (pH 7.2) buffer containing 250 mM NaCl. PAR exhibits an  $\epsilon_{\text{max}}$  at 500 nm in the  $\text{Zn}^{2+}$ -bound state. Background-corrected spectra were recorded at 25 °C.

### **tRNA aminoacylation activity assay**

Prolyl-tRNA aminoacylation was measured in a reaction mixture containing 150  $\mu\text{M}$  L-[ $^{14}\text{C}$ ]proline and 1 mg of total yeast tRNA in 20  $\mu\text{L}$  of assay buffer (20 mM HEPES, pH 8.0, 100 mM NaCl, 5 mM  $\text{MgCl}_2$ , 3 mM ATP, and 1 mM DTT). Reaction mixtures were pre-equilibrated at 37 °C, and initiated by addition of purified protein (2.5  $\mu\text{g}$ ) or lysate (2.5  $\mu\text{g}$ ), and incubated at 37 °C for 15 min. Aliquots (15  $\mu\text{L}$ ) were collected and spotted on glass filters (Whatman GF/C<sup>TM</sup>) presoaked with 5% trichloroacetic acid. Filters were

washed 3 × with 1 mL 5% trichloroacetic acid, followed by 2 × 1-mL washes with 100% ethanol. Filters were dried in a hybridization oven at 60 °C for 10 min and radioactivity quantified by liquid scintillation counting (TRI-CARB 1900TR, PerkinElmer Life Sciences).



## REFERENCES

- Chongdar, N., Dasgupta, S., Datta, A.B., and Basu, G. (2015). Dispensability of zinc and the putative zinc-binding domain in bacterial glutamyl-tRNA synthetase. *Biosci. Rep.* *35*.
- Halawani, D., Gogonea, V., DiDonato, J.A., Pipich, V., Yao, P., China, A., Topbas, C., Vasu, K., Arif, A., Hazen, S.L., et al. (2018). Structural control of caspase-generated glutamyl-tRNA synthetase by appended noncatalytic WHEP domains. *J. Biol. Chem.* *293*, 8843-8860.
- Huerta-Cepas, J., Serra, F., and Bork, P. (2016). ETE 3: reconstruction, analysis, and visualization of phylogenomic data. *Mol. Biol. Evol.* *33*, 1635-1638.
- Hunt, J.B., Neece, S.H., and Ginsburg, A. (1985). The use of 4-(2-pyridylazo)resorcinol in studies of zinc release from *Escherichia coli* aspartate transcarbamoylase. *Anal. Biochem.* *146*, 150-157.
- Jia, J., Arif, A., Ray, P.S., and Fox, P.L. (2008). WHEP domains direct noncanonical function of glutamyl-prolyl tRNA synthetase in translational control of gene expression. *Mol. Cell* *29*, 679-690.
- Scotto-Lavino, E., Du, G., and Frohman, M.A. (2006). 3' end cDNA amplification using classic RACE. *Nat. Protoc.* *1*, 2742-2745.